Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19

NCT04371978 is registered in ClinicalTrials.gov with Rabin Medical Center as lead sponsor.

NCT NCT04371978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04371978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
Lead sponsor
Rabin Medical Center
Phase
Phase 3
Overall status
Terminated
Start date
October 1, 2020
Completion date
May 4, 2021
Enrollment
64 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus, covid 19, diabetes mellitus, diabetes mellitus, type 2, dipeptidyl-peptidase iv inhibitors, endocrine system diseases, glucose metabolism disorders, hormones, hypoglycemic agents, incretins, linagliptin, metabolic disease, respiratory tract diseases, sars-cov2, severe acute respiratory syndrome coronavirus 2